ROTHSCHILD INVESTMENT LLC /IL - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 213 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.87 and the average weighting 0.3%.

Quarter-by-quarter ownership
ROTHSCHILD INVESTMENT LLC /IL ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2019$223,000
+10.9%
2,800
+40.7%
0.03%
-3.7%
Q4 2018$201,000
-19.9%
1,9900.0%0.03%
-10.0%
Q3 2018$251,000
-33.4%
1,990
-55.7%
0.03%
-36.2%
Q2 2018$377,000
+18.6%
4,490
-13.1%
0.05%
+14.6%
Q1 2018$318,000
+5.3%
5,1640.0%0.04%
+24.2%
Q4 2017$302,000
-10.9%
5,164
-11.7%
0.03%
-13.2%
Q3 2017$339,000
-41.6%
5,846
+22.0%
0.04%
-42.4%
Q2 2017$580,000
+7.0%
4,7920.0%0.07%
+4.8%
Q1 2017$542,000
+81.3%
4,792
+74.1%
0.06%
+75.0%
Q4 2016$299,000
-31.4%
2,752
+3.8%
0.04%
-32.1%
Q3 2016$436,000
+15.3%
2,6520.0%0.05%
+10.4%
Q2 2016$378,000
+10.9%
2,6520.0%0.05%
+9.1%
Q1 2016$341,000
-13.9%
2,6520.0%0.04%
-12.0%
Q4 2015$396,000
-10.0%
2,6520.0%0.05%
-13.8%
Q3 2015$440,000
-16.8%
2,652
+21.0%
0.06%
-4.9%
Q2 2015$529,000
-14.4%
2,1920.0%0.06%
-15.3%
Q1 2015$618,000
+80.7%
2,1920.0%0.07%
+75.6%
Q4 2014$342,0002,1920.04%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$39,083,0009.04%
Senvest Management, LLC 1,152,032$70,873,0005.40%
Melqart Asset Management (UK) Ltd 298,200$18,345,0002.20%
Elk Creek Partners, LLC 348,454$21,437,0001.25%
ALTRINSIC GLOBAL ADVISORS LLC 375,223$23,084,0000.93%
BB BIOTECH AG 545,719$33,573,0000.93%
Virtus ETF Advisers LLC 14,681$903,0000.78%
Opus Point Partners Management, LLC 4,496$277,0000.54%
Spark Investment Management LLC 136,500$8,397,0000.54%
Regal Investment Advisors LLC 29,511$1,816,0000.40%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders